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Abstract: From 1957 to 1962, thalidomide caused birth defects in >10,000 
children. While the drug was pulled from the market, thalidomide is 
currently prescribed to treat conditions including leprosy. As a result, 
a new generation of babies with thalidomide defects is being born in the 
developing world. This represents a serious problem, as the mechanisms by 
which thalidomide disrupts development remain unresolved. This lack of 
resolution is due, in part, to the absence of an appropriate mammalian 
model for thalidomide teratogenesis. We test the hypothesis that opossum 
(Monodelphis domestica) is well suited to model human thalidomide 
defects. Results suggest that opossum embryos exposed to thalidomide 
display a range of phenotypes (e.g., heart, craniofacial, limb defects) 
and penetrance similar to humans. Furthermore, all opossums with 
thalidomide defects exhibit vascular disruptions. Results therefore 
support the hypotheses that opossums make a good mammalian model for 
thalidomide teratogenesis, and that thalidomide can severely disrupt 
angiogenesis in mammals. 
 
 
 
 
Abstract 
From 1957 to 1962, thalidomide caused birth defects in >10,000 children. While the drug was 
pulled from the market, thalidomide is currently prescribed to treat conditions including leprosy. 
As a result, a new generation of babies with thalidomide defects is being born in the developing 
world. This represents a serious problem, as the mechanisms by which thalidomide disrupts 
development remain unresolved. This lack of resolution is due, in part, to the absence of an 
appropriate mammalian model for thalidomide teratogenesis. We test the hypothesis that 
opossum (Monodelphis domestica) is well suited to model human thalidomide defects. Results 
suggest that opossum embryos exposed to thalidomide display a range of phenotypes (e.g., heart, 
craniofacial, limb defects) and penetrance similar to humans. Furthermore, all opossums with 
thalidomide defects exhibit vascular disruptions. Results therefore support the hypotheses that 
opossums make a good mammalian model for thalidomide teratogenesis, and that thalidomide 
can severely disrupt angiogenesis in mammals. 
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Editor-in-Chief 
Reproductive Toxicology 
 
Dear Editor-in-Chief 
 
We are writing to respectfully request that you consider our revised manuscript, “A new 
mammalian model system for thalidomide teratogenesis: Monodelphis domestica” for 
publication in Reproductive Toxicology. The manuscript is being submitted for the upcoming 
special issue on development and angiogenesis. 
 
This study describes a new mammalian model for thalidomide defects in humans, the 
opossum (Monodelphis domestica). This represents an important step forward for the field that 
fills a critical gap in the field as, until now, there has not been an appropriate mammalian model 
for thalidomide teratogenesis in humans. Opossum embryos exposed to thalidomide display a 
range of phenotypes (e.g., heart, craniofacial, limb defects) and penetrance similar to humans, 
and opossums have larger litter sizes and are easy to breed in the lab. We were able to address all 
of the new reviewer comments (see below for details). We are thankful for the comments, and 
making the suggested changes improved the manuscript. 
 
Given its scope and relevance, this manuscript should be of interest to scientists with 
interests in teratology, thalidomide, developmental biology, and mammalian systems. As such, 
we are confident that Reproductive Toxicology readers will find this manuscript to be of general 
interest. Thank you for your consideration, and please feel free to contact us should you have any 
questions regarding our submission. 
 
Sincerely, 
 
  
  
 
465 Morrill Hall, 505 South Goodwin Avenue, Urbana IL 61801 
Cell: 217-898-3011, Email: ksears@life.illinois.edu, http://www.life.uiuc.edu/sears 
  
*Cover Letter
1. The authors continue to make statement or draw conclusions from data not in evidence in their 
paper. Specifically, in the second paragraph of the second full page of the Discussion the authors 
state "Given that opossums routinely have litters containing 8-15 embryos…" followed in the 
first line of the next paragraph which reads: Given the opossum's large litters…"  Table 1 of their 
data does not support these statements. In a total of 12 litters in this study, the mean number of 
embryos per litter is 7.5; 6/12 of the litters had ≤6 embryos only 4 litters had ≥10 embryos per 
litter.  Consequently, the first statement need a literature reference to support it and a brief 
discussion as to why this set of litters was so small.  In addition, the second statement might be 
reworded to state: "Given the opossum's litter size…" leaving out any subjective judgment as to 
size. 
 
KES: We have changed the language to reflect our findings in this study. “Given that the 
opossums from this study had an average of 7.5 embryos per litter, this means that most 
thalidomide-treated litters will likely produce many embryos displaying the “mildly deformed” 
phenotype and at least 1 embryo with the “severely deformed” phenotype. In line with this, all 
treated litters in our study generated several “mildly deformed” and at least 1 “severely 
deformed” embryo.” And “Given the opossum’s litter size, high penetrance of thalidomide-
induced defects, and defects similar to humans, this study strongly supports the hypothesis that 
the gray short-tailed opossum…” 
 
2. In the aforementioned paragraph, the discussion of the opossum placenta is weak or incorrect 
in several ways. First, the opossum has a choriovitelline placenta (which is not true of the 
eutherian mammals used in safety research - they possess inverted yolk sac placentae, which are 
quite different). Second, the choriovitelline placenta does not invade the uterine wall in any way 
similar to the invasions experienced by rodents or humans. Third, the lines that appear to equate 
"formation of placenta" in rodents or humans to opossums seems weak. It does appear that in 
their model thalidomide gets to the embryo by means of the choriovitelline placenta, but this is a 
strictly a diffusion driven model as opposed to the hemochorial arrangement in rodents and 
humans. Thus, this statement would needs to be qualified.  
 
KES: We have altered the text to read, “Furthermore, while the reproductive process of 
opossums, as marsupial mammals, does differ from that of humans and other placental mammals 
in some ways (e.g., choriovitelline placenta in marsupials vs. hemochorial placenta in humans), 
both marsupial and placental mammals share internal development, a reproductive trait critical to 
the process of teratogenesis. This similarity represents a significant advantage of the opossum 
model, relative to in vitro and non-mammalian models.” 
 
3. The last paragraph beginning at the bottom of the second page of the Discussion states: "The 
results of this study also strongly support the hypothesis that thalidomide can severely disrupt 
angiogenesis in mammals."  However, consideration of the new data and figures added to the 
paper need to be incorporated into the paragraph. In the last paragraph of the Results, the authors 
note "midbrain blood pooling" in a control embryo.  The authors need to deal with this finding in 
the Discussion. Certainly these data appear to weaken the statement about "strongly" supporting 
their hypothesis. I believe their hypothesis may have merit, but they need to provide the reader 
with rationale as to how this control embryo relates to their hypothesis.   
 
KES: We have removed the “strongly” from the discussion, and generally tempered our 
discussion language. We have also edited the text to the following, “The results of this study also 
support the hypothesis that thalidomide can severely disrupt angiogenesis in mammals. All 
embryos displaying a thalidomide-induced phenotype, be they “mildly deformed” or “severely 
deformed”, exhibited clear angiogenic defects. These defects ranged from hemorrhages and/or 
blood pooling in “mildly deformed” embryos to a complete vascular disruption in some 
“severely deformed” embryos. Moreover, while one of control embryo exhibits some isolated 
blood pooling, and thus some evidence for angiogenic disruption, the range (i.e., structures 
impacted) and magnitude (i.e., degree of severity) of disruptions displayed by treatment embryos 
is greater. These findings are therefore consistent with the hypothesis that thalidomide induces 
defects in mammals, including humans, at least in part by disrupting proper angiogenesis [21, 22, 
51].” 
 
4. Finally, the authors need to emphasize the preliminary nature of their data in their conclusions. 
The addition of control litters led to one litter with 2 severely malformed embryos. The veracity 
of this new model will require more historical control data being gathered - the authors are 
commended for starting this process and (potentially) sparking interest among other 
investigators. 
 
KES: We thank the reviewer for their comments. We have edited the final paragraph to the 
following, “To confirm the results obtained from the limited trials in this study, additional 
thalidomide and control trials should be performed in the opossum system. However, given the 
opossum’s litter size, high penetrance of thalidomide-induced defects, and defects similar to 
humans, results of this initial study support the hypothesis that the gray short-tailed opossum 
(Monodelphis domestica) makes a good mammalian model system for thalidomide-induced 
deformities in humas. In particular, the opossum system seems to provide a good opportunity to 
investigate the hypothetical role of vascular disruption in thalidomide teratogenesis… We are 
following up on the research presented here by performing additional thalidomide and control 
trials in opossum, and detailed analyses of the cellular and molecular processes that are disrupted 
by thalidomide exposure in the opossum model.” 
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*Response to Reviewer Comments
KES: We have removed the “strongly” from the discussion, and generally tempered our 
discussion language. We have also edited the text to the following, “The results of this study also 
support the hypothesis that thalidomide can severely disrupt angiogenesis in mammals. All 
embryos displaying a thalidomide-induced phenotype, be they “mildly deformed” or “severely 
deformed”, exhibited clear angiogenic defects. These defects ranged from hemorrhages and/or 
blood pooling in “mildly deformed” embryos to a complete vascular disruption in some 
“severely deformed” embryos. Moreover, while one of control embryo exhibits some isolated 
blood pooling, and thus some evidence for angiogenic disruption, the range (i.e., structures 
impacted) and magnitude (i.e., degree of severity) of disruptions displayed by treatment embryos 
is greater. These findings are therefore consistent with the hypothesis that thalidomide induces 
defects in mammals, including humans, at least in part by disrupting proper angiogenesis [21, 22, 
51].” 
 
4. Finally, the authors need to emphasize the preliminary nature of their data in their conclusions. 
The addition of control litters led to one litter with 2 severely malformed embryos. The veracity 
of this new model will require more historical control data being gathered - the authors are 
commended for starting this process and (potentially) sparking interest among other 
investigators. 
 
KES: We thank the reviewer for their comments. We have edited the final paragraph to the 
following, “To confirm the results obtained from the limited trials in this study, additional 
thalidomide and control trials should be performed in the opossum system. However, given the 
opossum’s litter size, high penetrance of thalidomide-induced defects, and defects similar to 
humans, results of this initial study support the hypothesis that the gray short-tailed opossum 
(Monodelphis domestica) makes a good mammalian model system for thalidomide-induced 
deformities in humas. In particular, the opossum system seems to provide a good opportunity to 
investigate the hypothetical role of vascular disruption in thalidomide teratogenesis… We are 
following up on the research presented here by performing additional thalidomide and control 
trials in opossum, and detailed analyses of the cellular and molecular processes that are disrupted 
by thalidomide exposure in the opossum model.” 
 
-Thalidomide-exposed opossums display phenotypes including severe blood pooling and 
hemorrhaging, limb truncations, digit losses, heart defects, and mandibular truncations.  
-Several thalidomide-induced phenotypes in opossums are similar to those observed in 
thalidomide-exposed humans, and thalidomide defects are similarly penetrant in opossums and 
humans. 
-All opossums with thalidomide defects exhibit vascular disruptions, consistent with thalidomide 
being a disrupter of blood vessel formation. 
-Phenotypic results of this study suggest that opossums might make a good mammalian model 
for thalidomide teratogenesis, and set the stage for further thalidomide research in opossum. 
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Abstract 
From 1957 to 1962, thalidomide caused birth defects in >10,000 children. While the drug was 
pulled from the market, thalidomide is currently prescribed to treat conditions including leprosy. 
As a result, a new generation of babies with thalidomide defects is being born in the developing 
world. This represents a serious problem, as the mechanisms by which thalidomide disrupts 
development remain unresolved. This lack of resolution is due, in part, to the absence of an 
appropriate mammalian model for thalidomide teratogenesis. We test the hypothesis that 
opossum (Monodelphis domestica) is well suited to model human thalidomide defects. Results 
suggest that opossum embryos exposed to thalidomide display a range of phenotypes (e.g., heart, 
craniofacial, limb defects) and penetrance similar to humans. Furthermore, all opossums with 
thalidomide defects exhibit vascular disruptions. Results therefore support the hypotheses that 
opossums make a good mammalian model for thalidomide teratogenesis, and that thalidomide 
can severely disrupt angiogenesis in mammals. 
 
  
Introduction 
Thalidomide was originally marketed in 1957 as a non-barbiturate sedative. The drug’s mild side 
effects on the patient made it incredibly popular in the treatment of morning sickness. Two years 
later it was realized that thalidomide was causing a wide spectrum of very serious birth defects, 
and the drug was removed from the market [1-4]. Thalidomide most commonly induced birth 
defects in the limbs, and these defects ranged from amelia to phocomelia to digit loss [3, 5, 6]. 
Other thalidomide-induced defects included ear and eye problems, genital abnormalities, 
peripheral neuropathies, and internal organ defects (primarily to the kidneys, lungs, intestinal 
tract, and heart). Ultimately over 10,000 children worldwide were born with severe birth defects 
as a result of the teratogenic activities of thalidomide [2, 3, 7-10]. Despite its sordid history, 
thalidomide has reemerged as a treatment for multiple conditions including erythema nodosum 
leprosum, multiple myeloma, Crohn’s Disease, and AIDS [11-17]. Unfortunately, this revival 
has been accompanied by a second generation of children with thalidomide-induced birth defects 
[18, 19], and highlighted the need for a complete understanding of the developmental 
mechanisms of thalidomide teratogenesis. In this study we develop a new model organism for 
the study of the cellular and molecular basis of thalidomide teratogenesis, the gray short-tailed 
opossum (Monodelphis domestica). 
 
Despite its long and devastating history, the teratogenic mechanisms of thalidomide are not yet 
fully understood. Dozens of distinct theories for the mechanisms of thalidomide teratogenesis 
have been proposed, including DNA mutagenesis, disruption of chondrogenesis, nerve or neural 
crest toxicity, and inhibition of cell adhesion molecules [20, 21]. Currently, the most widely 
supported theories for thalidomide teratogenesis are based on the drug’s abilities to disrupt 
angiogenesis [22-25]. The lack of resolution as to the mechanisms by which thalidomide 
generates human birth defects and the early misuse of the drug are primarily due to the 
complexity of the mechanisms themselves, and the lack of an appropriate mammalian model 
study system for thalidomide teratogenesis. Traditional mammal models, such as rats and mice, 
are resistant to the teratogenic properties of thalidomide. Though susceptible, studies of rabbit 
and other primates are hampered by the number of affected embryos that can be obtained. As a 
result, much of what is currently known about the mechanisms through which thalidomide acts 
has come from studies of zebrafish embryos, chicken embryos, or human umbilical vein 
endothelial cells (HUVECS) [22, 26-30]. Although research in these systems has provided 
important insights into thalidomide teratogenesis, these systems have limitations. Though 
zebrafish and chicken embryos display thalidomide induced appendage deformation, their 
possession of fins and wings rather than limbs limits what can be learned about the characteristic 
thalidomide limb deformities in humans [31]. HUVECS lack a developmental and cross-tissue 
context, and this limits what can be learned from them about the mechanisms by which 
thalidomide generates deformities in the embryo. 
 
In this study we test the hypothesis that the gray short-tailed opossum (Monodelphis domestica) 
is well suited to model human thalidomide induced deformities. Opossums have large litters (up 
to 13 pups are born, through more embryos are sometimes present in the uterus), are easy to 
maintain and breed in the lab [32-34], have a fully sequenced and well-annotated genome [35], 
and are a well-established study system for development [35-42]. Opossums also display a 
unique mode of limb development in which the forelimbs grow at twice the rate of the hind 
limbs, which provides two temporal opportunities to study the impacts of teratogens on limb 
development [34, 43, 44]. Opossum forelimbs begin to grow out from the body at embryonic day 
(E) 10.75, form a bud at E11.3, a paddle at E11.75, and by E13.75 the interdigital webbing has 
reduced and the digits are free. Opossum forelimbs therefore go from initial outgrowth to free 
digit formation in about 3 days. Opossum hind limbs first grow out from the body at E11.7, are 
buds at E12.2, and paddles shortly before birth at ~E14. The hind limbs complete their 
development after birth. For comparison purposes, mice limbs begin to grow out from the body 
at E9, form a bud at E11, a paddle at E12, and free digits at E15 – E16 [45]. However, despite 
the uniqueness of the timing of opossum limb development, most of the primary cellular and 
molecular drivers of limb development are highly conserved in opossum and other mammals 
[36-38, 45, 47]. 
 
While the traits listed above make opossums a good model organism in general, for opossums to 
make a suitable mammalian model for thalidomide teratogenesis in humans they must be 
susceptible to thalidomide and display thalidomide-induced phenotypes that are similar to those 
observed in humans exposed to the drug. To evaluate whether opossums meet these criteria, we 
treated pregnant opossums with thalidomide and evaluated the impact of the thalidomide 
treatments on the morphology of the embryos.  
 
Methods 
Tissue Collection – All procedures described below have been approved by the University of 
Illinois IACUC. The Sears Lab (University of Illinois) maintains a breeding colony of opossums 
(Monodelphis domestica) using established protocols [32-34]. This colony is comprised of 
pedigreed animals from the Texas Biomedical Research Institute (San Antonio, TX) and their 
descendants. To generate timed matings, opossum males and females are placed together and 
recorded using infrared cameras [37]. The time at which mating occurs is defined as the time of 
conception. 
 
Pregnant females were treated with a thalidomide (Sigma, N = 7) or control solution (N = 5) 
10.75 days after conception through intraperitoneal (IP) injection, when embryos should be at 
Stage 26 (E10.75) [46, 47]. Stage 26 was selected for use because opossum organ development 
at this stage generally corresponds to the critical period of thalidomide sensitivity in humans, 
which is between 20 and 36 days after fertilization [7, 12, 48]. Thalidomide was delivered to 
each animal in solution at doses of 20 mg/kg. As a point of reference, adult, female opossums 
generally weigh between 80 and 100 grams [31, 32]. The thalidomide solution contained the 
appropriate amount of thalidomide (for the body weight of the female) dissolved in phosphate 
buffered saline (PBS) with 1% carboxymethyl cellulose and 1% dimethyl sulfoxide (DMSO), 
and the control the same but without the thalidomide. A total of 100l of thalidomide solution 
was injected into each female. Females were monitored for overt, external signs of toxicity or 
stress (e.g., scruffy fur, loss of body weight, hunched posture, poor activity, difficulty breathing, 
shaking/shivering, dehydration, etc.). Pregnant females were euthanized by carbon dioxide 
inhalation to effect followed by cervical dislocation, and embryos dissected from the uterus and 
staged [46, 47].  
 
To assess the morphology of thalidomide-exposed embryos, pregnant opossums were euthanized 
3 days post-treatment at 13.75 days post-conception, shortly before birth (opossums are usually 
born between 14 and 15 days post-conception) [46]. Embryos dissected at this time should be at 
Stage 33 [46, 47]. Embryos (N = 60 treatment, N = 30 control) were immediately examined and 
photographed using a Leica M205 C microscope and a Leica DFC425 digital microscope camera 
(Leica Microsystems Inc., Buffalo Grove, IL). While Stage 33 opossums are at an early stage of 
development (e.g., ossification has not yet begun), and a later developmental stage might be 
better for comparative purposes, the thalidomide-treated opossums do not usually survive after 
birth. While it is difficult to conclusively diagnose phocomelia at this early developmental stage 
(i.e., pre-ossification), many other birth defects are readily-apparent (e.g., blood vessel 
disruption, craniofacial defects, other limb defects, etc.). 
 
Results 
We did not observe any overt, external signs of toxicity or stress in the treated adult females. 
Three major phenotypes are present among the 60 thalidomide-treated embryos (from 7 litters) 
that were generated by this study. There was no evidence of any resorptions. We have classified 
these phenotypes as “normal”, “mildly deformed”, and “severely deformed.” A breakdown of 
embryo numbers and phenotypes by litter is provided in Table 1. 
 
The external morphologies of embryos with the “normal” phenotype appear to have been 
unaffected by the thalidomide treatment. This phenotype class makes up 32% (N=19) of the 
treated embryos. Embryos from this class are full size, have normal proportions, and do not 
display any visible deformities (Figure 1A). In two “normal” embryos, the amniotic sac was 
constricted around the embryo just anterior to the hindlimb (e.g., amniotic band syndrome). 
 
Most treated embryos, 57% (N = 34), display the “mildly deformed” phenotype. “Mildly 
deformed” embryos occur in all treated litters (Figure 1B). These embryos are indistinguishable 
from control embryos in terms of overall size and limb patterning. Heartbeats can be visualized 
upon removal from the mother. However, all mildly deformed treated embryos present with at 
least one region of severe internal hemorrhaging and blood pooling, as was also seen in prior 
studies in monkeys [49]. These regions are commonly located near or in the fore- (N = 14) or 
hind (N = 9) limb, in the brain (N = 17), or in the abdominal cavity (N = 17) (Table 2). In most 
regions, these hemorrhages tend to be asymmetrical. However, hemorrhaging in the region of the 
hind limbs tends to occur symmetrically. In about half of “mildly deformed” embryos (N = 19), 
the hemorrhaging and blood pooling (N = 19) is restricted to one general region (i.e., brain, fore- 
or hind limb, abdominal cavity). In the other half, the hemorrhaging and blood pooling is present 
in two (N = 10), three (N = 4), or all four general regions (N = 1). In two “mildly deformed” 
embryos, the amniotic sac was constricted around the embryo just anterior to the hindlimb (e.g., 
amniotic band syndrome). However, these two embryos did not display any signs of 
morphological deformation or size reduction. 
 
Treated embryos displaying the “severely deformed” phenotype, 12% (N = 7) exhibit a severely 
affected but variable external morphology. All treated embryos from this class are roughly or 
less than half the size of unaffected or mildly affected littermates, and all but one lacks 
pigmentation in the eye. As other physical traits vary among treated embryos, we describe each 
“severely deformed” treated embryo below.  
 The least deformed of the “severely deformed” treated embryos (Embryo A) displays a novel 
amniotic sac defect (Figure 2A). Instead of a normal single amniotic sac, the amniotic sac has 
split into two chambers: one surrounding the embryo and one connecting to the chorionic plate. 
The embryo also displays significant hemorrhaging around its heart (Figure 2B). The heart itself 
is a small mass of improperly organized tissue beneath a single membrane, when it should be 
fully enclosed in the thoracic cavity by this point in development. While the cranial medial 
portion of the face appears to be normal above the jaw, there is no apparent mouth opening and 
the lateral portions of the cranium are missing or remarkably reduced in size. The forelimb is 
severely stunted, and displays a symmetrical loss of the first and fifth digits that results in a 
narrowed autopod. The hindlimb appears to be normal. 
 
We observed similar amniotic defects, i.e., a dual-chambered amniotic sac, in another of the 
“severely deformed” treated embryos (Embryo B; Figure 2C). This embryo also has a large 
hemorrhage on the ventral surface around the heart, and its vascular networks appear immature 
with none of the major blood vessels evident (Figure 2D). The medial-rostral face of this embryo 
is also heavily deformed. Specifically, the medial portion of the mandibular process is severely 
reduced and the medial nasal process is completely absent. The cranial portion of the head also 
appears reduced in size. However, the limbs appear to be normally patterned despite the overall 
size reduction. Similar to Embryo A, this embryo appears to have been viable at least until the 
point of dissection as it has several traits that are characteristic of Stage 33 (E13.75) of opossum 
development (e.g., reduction in interdigital tissue, protruding tongue).  
 
The remaining “severely deformed” treated embryos (Embryos C, D, E, F, and G) present none 
of the characteristics of Stage 33 (E13.75) of opossum development and most do not have visible 
blood flow. As a result, these embryos were not clearly viable at the time of dissection. Only one 
of these embryos, Embryo C (Figure 2E), has some minimal blood flow, although no major 
arteries are evident. However, the entire rostral portion of the cranium of Embryo C is greatly 
reduced, as is the region of embryo that is posterior to the forelimb. The digits of the forelimbs of 
Embryo C have also failed to differentiate properly and protrude at abnormal and asymmetrical 
angles.  
 
Two “severely deformed” treated embryos from the same litter, Embryos D and E, display 
similar defects (D shown in Figure 2F). Neither embryo contains enough blood to visualize a 
vascular network. Though the faces of these embryos were damaged during dissection, both still 
clearly display a significantly reduced mandibular process. The hind limbs of both embryos are 
reduced in size and remain at an immature bud stage, similar to that observed at Stage 30 
(E11.75) or 31 (E12.2) of opossum development [46]. The forelimbs of both embryos display an 
abnormal posterior orientation.  
 
The forelimbs of another “severely deformed” treated embryo, Embryo F, are normal in their 
medial-lateral patterning (Figure 2G). They are, however, missing a single digit leaving the 
remaining digits in a symmetrical arrangement. The vascular network of Embryo F is also 
incomplete and disorganized. 
 
The most disfigured of the treated embryos, Embryo G, is less than a third of the length of the 
“mildly deformed” and control embryos (Figure 2H and 2I). The vasculature of this embryo is 
limited to a few, very small pools of blood. Embryo G’s limbs are also highly asymmetrical. The 
left limb resembles an enlarged version of the limb bud of a normal opossum at developmental 
Stage 28 [46]. The right limb is severely truncated in both width and length.  Much of the cranial 
morphology of this embryo is unidentifiable due to gross deformity but the rostral region of the 
head appears to be absent or much reduced. 
 
This study also generated 30 control embryos from 5 litters for which the DMSO/CMC mixture 
used to dissolve thalidomide was injected alone. All embryos from four of the litters (N = 25), 
and 2 embryos from the fifth display normal phenotypes (Figures 3A and 3B), resulting in 90% 
of control embryos displaying normal phenotypes. Three embryos from the fifth litter, all of 
which were from a single uterine horn which was noted to be smaller than normal uterine horns 
at similar stages of pregnancy upon dissection, display some degree of malformation or 
developmental delay. The least deformed of these embryos exhibits mild blood pooling in the 
midbrain region and in small, isolated patches elsewhere on the body (e.g., forelimb, neck, back) 
(Figure 3C). While this embryo appears to display a midbrain blood pooling phenotype similar to 
that observed in 14 of the 60 “mild phenotype” thalidomide treated embryos described above, it 
does not display pooling in other regions in which pooling was commonly observed in “mild 
phenotype” treated embryos (e.g., forebrain in 9 embryos, on body ventral or dorsal to forelimb 
in 12 embryos). The other two control embryos are smaller in size, with one at 63% (Figure 3D) 
and the other 44% (Figure 3E) of the size of normal, control embryos. However, despite their 
size, both embryos display grossly normal limb phenotypes, with the larger displaying a paddle-
like forelimb and bud-like hind limb similar to those of Stage 30 opossum embryos, and the 
smaller bud-like forelimbs and no perceivable hind limbs similar to Stage 28 embryos. 
Furthermore, neither embryo displays significant blood pooling or hemorrhaging, amniotic sac 
defects, heart defects, or perceivable mandibular defects. 
 
Discussion 
Embryonic opossums that have been exposed to thalidomide replicate many of the birth defects 
observed in humans that have been exposed to the drug [2, 3, 5-8]. These defects include limb 
truncations, digit losses, eye defects, craniofacial defects, developmental delays, reductions in 
overall size, vascular disruption, and heart defects. However, while we did observe limb 
truncations, we cannot conclusively state that any represent phocomelia because of the early 
developmental stages of the embryos (i.e., pre-ossification). 
 The thalidomide-induced defects produced in this study differ from those produced in opossums 
exposed to retinoic acid, another teratogen, in a previous study (i.e., highly penetrant 
oligodactyly, exencephaly, no vascular disruption, etc.) [37]. In addition, control embryos 
generated in this study did not recapitulate several of the phenotypes observed in thalidomide-
treated embryos, including severe and widely distributed blood pooling and hemorrhaging, limb 
truncations, digit losses, heart defects, and mandibular truncations. Taken together, these 
findings are consistent with these phenotypes being thalidomide-specific in opossums.  
 
Thalidomide-exposed opossums also display phenotypes that have not previously been described 
in thalidomide-exposed animals, most notably amniotic sac defects. We observed amniotic sac 
constrictions both on and separate from the developing embryo after treatment with thalidomide. 
The relatively complete and normal development of the embryos inside some of these 
constrictions suggests that the constriction likely resulted from the fusion of the amniotic sac 
later in the pregnancy, rather than from defects in initial sac patterning. Alternatively, the 
constrictions could represent non-embryonated vesicles. While the cause of these amniotic sac 
defects remains unknown, the constriction we observed could be a cause of some of the less 
commonly seen thalidomide defects, such as the absence of the distal portions of the digits. In 
line with this, many of these less commonly observed thalidomide-induced defects in humans 
closely resemble those caused by the prenatal constrictions in amniotic band syndrome, so much 
so that the two disorders can be mistaken for each other [50].   
 
The results of this study also support the hypothesis that thalidomide can severely disrupt 
angiogenesis in mammals. All embryos displaying a thalidomide-induced phenotype, be they 
“mildly deformed” or “severely deformed”, exhibited clear angiogenic defects. These defects 
ranged from hemorrhages and/or blood pooling in “mildly deformed” embryos to a complete 
vascular disruption in some “severely deformed” embryos. Moreover, while one of control 
embryo exhibits some isolated blood pooling, and thus some evidence for angiogenic disruption, 
the range (i.e., structures impacted) and magnitude (i.e., degree of severity) of disruptions 
displayed by treatment embryos is greater. These findings are therefore consistent with the 
hypothesis that thalidomide induces defects in mammals, including humans, at least in part by 
disrupting proper angiogenesis [21, 22, 51]. 
 
Unlike some other mammalian species that have been investigated [52, 53], thalidomide-induced 
birth defects are relatively easy to generate in opossums. Opossum embryos display a 60% 
penetrance of the “mildly deformed” phenotype and a 12% penetrance of the “severely 
deformed” phenotype. This is consistent with human case reports, which estimate that 
approximately 20-50% of thalidomide exposed infants were born with abnormalities [3, 7, 48]. 
Given that the opossums from this study had an average of 7.5 embryos per litter, this means that 
most thalidomide-treated litters will likely produce many embryos displaying the “mildly 
deformed” phenotype and at least 1 embryo with the “severely deformed” phenotype. In line 
with this, all treated litters in our study generated several “mildly deformed” and at least 1 
“severely deformed” embryo. 
 
To confirm the results obtained from the limited trials in this study, additional thalidomide and 
control trials should be performed in the opossum system. However, given the opossum’s litter 
size, high penetrance of thalidomide-induced defects, and defects similar to humans, results of 
this initial study support the hypothesis that the gray short-tailed opossum (Monodelphis 
domestica) makes a good mammalian model system for thalidomide-induced deformities in 
humans. In particular, the opossum system seems to provide a good opportunity to investigate 
the hypothetical role of vascular disruption in thalidomide teratogenesis. Furthermore, while the 
reproductive process of opossums, as marsupial mammals, does differ from that of humans and 
other placental mammals in some ways (e.g., choriovitelline placenta in marsupials vs. 
hemochorial placenta in humans), both marsupial and placental mammals share internal 
development, a reproductive trait critical to the process of teratogenesis. This similarity 
represents a significant advantage of the opossum model, relative to in vitro and non-mammalian 
models. We are following up on the research presented here by performing additional 
thalidomide and control trials in opossum, and detailed analyses of the cellular and molecular 
processes that are disrupted by thalidomide exposure in the opossum model. 
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Table 1. Phenotypes of treated and control embryos at Stage 33, by litter. 
 
  
 
Total 
embryos 
Normal 
Phenotype 
% 
Normal 
Mild 
Phenotype 
% 
Mild 
Severe 
Phenotype 
% 
Severe 
Treated Litter 1 12 4 33 6 50 2 17 
Treated Litter 2 13 3 23 9 69 1 8 
Treated Litter 3 9 1 11 8 89 0 0 
Treated Litter 4 6 3 50 3 50 0 0 
Treated Litter 5 10 4 40 5 50 1 10 
Treated Litter 6 5 1 20 4 80 0 0 
Treated Litter 7 5 1 20 1 20 3 60 
Control Litter 1 10 10 100 0 0 0 0 
Control Litter 2 4 4 100 0 0 0 0 
Control Litter 3 3 3 100 0 0 0 0 
Control Litter 4 8 8 100 0 0 0 0 
Control Litter 5 5 2 40 1 20 2 40 
Table 2. Sites of hemorrhages and/or pooled blood in embryos displaying the “mildly deformed” 
phenotype. Embryos with multiple hemorrhages are listed in more than one row in upper section 
of table. % of treated embryos is out of the total number of thalidomide-treated embryos, N = 60. 
 
Location 
Number of embryos 
displaying phenotype 
% of treated 
embryos (N=60) 
BRAIN 17 28 
Forebrain 9 15 
Midbrain 13 22 
Brain stem 6 10 
ABDOMINAL 17 28 
FORELIMB ASSOCIATED 14 23 
On body, just ventral to forelimb 5 8 
On body, just dorsal to forelimb 8 13 
Upper and fore- arm 2 3 
Hand 5 8 
HIND LIMB ASSOCIATED 9 15 
Upper and fore- leg 9 15 
Foot 1 2 
   Co-occurrence of locations  
 ONE LOCATION 19 32 
Brain 7 12 
Abdominal 5 8 
Forelimb 3 5 
Hind limb 4 7 
TWO LOCATIONS 10 17 
Brain + abdominal 2 3 
Brain + forelimb 2 3 
Brain + hind limb 1 2 
Abdominal + forelimb 3 5 
Abdominal + hind limb 2 3 
Forelimb + hind limb 0 0 
THREE LOCATIONS 4 7 
Brain + abdominal + forelimb 3 5 
Brain + abdominal + hind limb 0 0 
Brain + forelimb + hind limb 1 2 
Abdominal + forelimb + hind limb 0 0 
FOUR LOCATIONS 1 2 
Figure 1. Both embryos in this figure were exposed to thalidomide at Stage 26 and dissected at 
Stage 33. The embryo on the left (A) does not display any phenotype, i.e., is from the “normal” 
phenotype class, and that on the right (B) is from the “mildly deformed” class. Most embryos 
that have been exposed to thalidomide display a “mildly deformed” phenotype, similar to the 
embryo in (B), that is characterized by hemorrhaging and blood pooling in various regions of the 
embryo. Arrows indicate patches of blood pooling. 
 
Figure 2. Several thalidomide-exposed embryos display “severely deformed” phenotypes, but the 
phenotypes of these embryos vary. Shown here are the amniotic sac phenotype (A) and anatomy 
(B) of Embryo A, the amniotic sac phenotype (C) and anatomy (D) of Embryo B, and the 
anatomy of Embryos C (E), D (F), E (G), and F (H, I). All scale bars represent 0.25mm. 
 
Figure 3. Most control embryos (N = 22, 90%) display a “normal” phenotype (A, B). Three 
control embryos, all coming from one uterine horn of a single litter, display either blood pooling 
(C) or smaller than normal sizes (D and E). However, none of the control embryos display severe 
and widely distributed blood pooling and hemorrhaging, limb truncations, digit losses, heart 
defects, or mandibular truncations.  
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